Holen Sie sich die Stockscreener-App
12.94
4.19%
0.52
Handel nachbörslich:
12.86
-0.08
-0.62%
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
Theravance Biopharma Second Quarter 2025 Earnings: EPS Beats Expectations - uk.finance.yahoo.com
Theravance Biopharma (NASDAQ:TBPH) shareholder returns have been respectable, earning 51% in 1 year - simplywall.st
Theravance Biopharma, Inc. SEC 10-Q Report - TradingView
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Theravance Biopharma stock price target raised to $13 by Leerink Partners By Investing.com - Investing.com Nigeria
Theravance Biopharma stock price target raised to $13 by Leerink Partners - Investing.com UK
Theravance Biopharma Q2 2025 Earnings Call Transcript - MarketBeat
Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ... - Yahoo Finance
Theravance Sales Jump 83 Percent - AOL.com
Theravance anticipates $150M in milestones as CYPRESS trial nears pivotal data readout - MSN
Technical signs of recovery in Theravance Biopharma Inc. [Analyst Upgrade]Free Safe Entry Momentum Stock Tips - Newser
Theravance Biopharma Reports Strong Q2 2025 Results - TipRanks
Theravance Sales Jump 83 Percent - The Motley Fool
Theravance Biopharma (TBPH): A High-Conviction Play on Rare Disease Innovation and Durable Cash Flow - AInvest
Contradictions Unveiled: Theravance Biopharma's 2025Q2 Earnings Call Highlights Pricing, Strategy, and Market Dynamics - AInvest
Theravance Biopharma's Q2 Surge: A Case Study in Biotech Resilience and Strategic Precision - AInvest
Earnings call transcript: Theravance Biopharma Q2 2025 earnings beat expectations - Investing.com
What institutional flow reveals about Theravance Biopharma Inc.Trade Safety Matrix for Conservative Traders - Newser
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Theravance Bio: Q2 Earnings Snapshot - San Francisco Chronicle
Theravance Biopharma Q2 2025 slides: Revenue jumps 22%, cash position triples - Investing.com Canada
Theravance Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
THERAVANCE BIOPHARMA Earnings Results: $TBPH Reports Quarterly Earnings - Quiver Quantitative
Theravance Biopharma earnings beat by $0.41, revenue topped estimates - Investing.com Canada
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Is Theravance Biopharma Inc. still worth holding after the dipFree Smart Money Tracking Signal Generator - Newser
Technical signs of recovery in Theravance Biopharma Inc.Daily Profit Watch With Forecast Confidence - Newser
Theravance Biopharma Inc.’s volatility index tracking explainedTrend Confirmation Scanner with Entry Focus - Newser
Signal strength of Theravance Biopharma Inc. stock in tech scannersRisk Aware Trading Ideas with Alert Levels - Newser
Real time pattern detection on Theravance Biopharma Inc. stockIntraday Signal Forecast for Fast Traders - Newser
Price momentum metrics for Theravance Biopharma Inc. explainedFree News Based Entry Opportunity Alerts - Newser
Tools to monitor Theravance Biopharma Inc. recovery probabilitySwing Watchlist With Tight Stop Placement - Newser
Using data models to predict Theravance Biopharma Inc. stock movementSmart Stock Forecast Using AI Algorithms - Newser
Theravance Biopharma (TBPH) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Moving Average Trends for Theravance Biopharma Inc. Stock: What They IndicateTechnical Entry Plan with Risk Minimization - Newser
Theravance Biopharma Inc expected to post earnings of 67 cents a shareEarnings Preview - TradingView
Theravance Biopharma Inc. Stock Performance After Earnings: Historical InsightsFree Conservative Entry for High Return Setup - Newser
What makes Theravance Biopharma Inc. stock price move sharplyHigh Conviction Screener with Trend Matching - Newser
How Theravance Biopharma Inc. stock performs during market volatilitySmart Trade Forecast Based on Neural Logic - Newser
Technical Charts Suggest Momentum Shift in Theravance Biopharma Inc.Chart Driven Price Action Analysis - beatles.ru
What’s the recovery path for long term holders of Theravance Biopharma Inc.Free ROI Boosting Trade Opportunity Calendar - Newser
What is the dividend policy of Theravance Biopharma Inc. stockInvest confidently with professional market insights - Jammu Links News
Is Theravance Biopharma Inc. stock overvalued or undervaluedInvest confidently with actionable market data - Jammu Links News
What are the latest earnings results for Theravance Biopharma Inc.Maximize gains with timely market signals - Jammu Links News
What are the technical indicators suggesting about Theravance Biopharma Inc.High-velocity gains - Jammu Links News
How volatile is Theravance Biopharma Inc. stock compared to the marketBreakthrough profits - Jammu Links News
What analysts say about Theravance Biopharma Inc. stockSuperior returns - Jammu Links News
Should I hold or sell Theravance Biopharma Inc. stock in 2025Build a diversified portfolio for risk management - Jammu Links News
What is Theravance Biopharma Inc. company’s growth strategyMaximize your gains with professional insights - Jammu Links News
What drives Theravance Biopharma Inc. stock priceAchieve rapid returns with smart investment plans - Jammu Links News
How strong is Theravance Biopharma Inc. company’s balance sheetAchieve breakthrough results with expert guidance - Jammu Links News
Why is Theravance Biopharma Inc. stock attracting strong analyst attentionHigh-profit capital plays - Jammu Links News
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):